Novel Approaches and FormulationsPeptide and Recombinant Immunotherapy
Section snippets
Recombinant allergens for immunotherapy
Reduction in the allergenicity of allergens has been achieved in a variety of ways through the use of recombinant DNA technology. Individual point mutations at sites contributing to protein folding and conformational epitopes have resulted in molecules that retain many T-cell epitopes while displaying IgE reactivity diminished by several orders of magnitude.9, 10, 11, 12, 13, 14, 15, 16, 17, 18 Alternative approaches include the generation of multiallergen hybrid molecules19, 20, 21, 22; the
Summary
Because of the need to standardize allergen immunotherapy coupled with the desire to reduce allergic adverse events during therapy, a transition to recombinant/synthetic hypoallergenic approaches is inevitable in the near future. Mounting evidence supports the notion that effective therapy can be delivered using a limited panel of allergens or even epitopes, weakening the argument that all allergens must be present (eg, in an extract) for optimal efficacy. Moreover, standardized products will
References (74)
- et al.
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology
Ann Allergy Asthma Immunol
(1998) - et al.
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond
J Allergy Clin Immunol
(2011) - et al.
Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy
FEBS Lett
(1998) - et al.
Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2
Arch Biochem Biophys
(1997) - et al.
A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy
J Allergy Clin Immunol
(2005) - et al.
Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens
J Allergy Clin Immunol
(2001) - et al.
Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial
J Allergy Clin Immunol
(2003) - et al.
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial
Lancet
(2002) - et al.
Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen
J Allergy Clin Immunol
(1999) - et al.
Allergen-specific immunotherapy with recombinant grass pollen allergens
J Allergy Clin Immunol
(2005)
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis
J Allergy Clin Immunol
Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v. 1 trimer
Mol Immunol
Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity
J Allergy Clin Immunol
Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome
J Allergy Clin Immunol
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
J Allergy Clin Immunol
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy
J Allergy Clin Immunol
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses
J Immunol Methods
Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes
J Biol Chem
Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein
J Allergy Clin Immunol
Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy
Immunol Allergy Clin North Am
A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen
Clin Immunol
Effects of peptide therapy on ex vivo T-cell responses
J Allergy Clin Immunol
Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats
J Allergy Clin Immunol
The safety and efficacy of ALLERVAX CAT in cat allergic patients
Clin Immunol
Update on the current status of peptide immunotherapy
J Allergy Clin Immunol
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom
J Allergy Clin Immunol
Long-term clinical efficacy of grass-pollen immunotherapy
N Engl J Med
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years
J Allergy Clin Immunol
SQ-standardised grass tablet sublingual immunotherapy: persistent clinical benefit and progressive immunological changes during three years treatment
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M
Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis
Allergy
Immunotherapy in asthma: an updated systematic review
Allergy
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study
Allergy
Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis
Adv Exp Med Biol
Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy
Eur J Immunol
A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy
J Immunol
Modification of a major peanut allergen leads to loss of IgE binding
Int Arch Allergy Immunol
Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation
Int Arch Allergy Immunol
Cited by (11)
Effect of Vitamin D Adjuvant and Allergen Specific Immunotherapy on Serum IL-10 and IL-17 Levels in Childhood Asthma: A Controlled Clinical Trial
2021, Egyptian Journal of Medical Microbiology (Egypt)Modified Allergens for Immunotherapy
2018, Current Allergy and Asthma ReportsAllergen extracts for immunotherapy: To mix or not to mix?
2016, Expert Review of Clinical PharmacologyFirst successful reduction of clinical allergenicity of food by genetic modification: Mal d 1-silenced apples cause fewer allergy symptoms than the wild-type cultivar
2015, Allergy: European Journal of Allergy and Clinical ImmunologyThe effect of Vitamin D supplementation on subcutaneous allergen immunotherapy in house dust mite sensitive asthmatic children
2015, Turkish Journal of ImmunologyIn silico structural analysis of group 3, 6 and 9 allergens from Dermatophagoides farinae
2015, Molecular Medicine Reports
The author is funded by the Canada Research Chairs program, the Canadian Institutes for Health Research, AllerGen Network of Centres of Excellence, the Canadian Foundation for Innovation, the Ontario Thoracic Society, Adiga Life Sciences Inc and the McMaster University/GSK endowed Chair in Lung Immunology at St Joseph’s Healthcare.
Disclosure. The author is a founder, shareholder and consultant of/to Circassia Ltd., a company developing peptide-based immunotherapy. The author is scientific founder of Adiga Life Sciences Inc, A joint venture between Circassia Ltd and McMaster University.